2026 Review,serves a central role in viral fusion with the host cell

The HIV fusion peptide (FP) is a crucial element in the lifecycle of the Human Immunodeficiency Virus (HIV), playing a pivotal role in its ability to infect host cells. Located at the N terminus of the envelope (Env) glycoprotein, specifically the gp41 subunit, this short sequence of hydrophobic amino acids is essential for the virus to merge its membrane with that of a target cell, thereby initiating infection. Understanding the structure and function of the HIV-1 fusion peptide is not only fundamental to comprehending viral entry mechanisms but also holds significant promise for the development of effective HIV vaccine strategies.

The process of viral entry is a complex cascade initiated by the binding of the HIV envelope (Env) glycoprotein to host cell receptors, primarily CD4 and a coreceptor. This binding triggers conformational changes within the Env protein, leading to the exposure of the N-terminal fusion peptide of gp41. This exposed peptide then translocates and inserts itself into the target cell membrane. This initial insertion is a critical step that destabilizes the cellular membrane, setting the stage for the subsequent refolding of gp41 to drive the fusion of the viral and cellular membranes. Research has shown that the HIV-1 fusion peptide can penetrate, disorder, and soften T-cell membranes, highlighting its direct interaction with and disruption of cellular structures.

The HIV fusion peptide is not merely an entry facilitator; it is also recognized as a vulnerable site on the virus. This vulnerability has made it a prime target for neutralizing antibodies. Studies have identified the fusion peptide as a site of vulnerability to neutralizing antibodies, and it is now understood to be a neutralizing antibody epitope, making it a key target for vaccine design. The development of HIV-1 fusion peptide immunogens aims to elicit robust immune responses that can effectively neutralize the virus by targeting this conserved region. This approach is crucial for designing potent and broad HIV-1 neutralization strategies.

Furthermore, the HIV fusion peptide has been investigated for its potential in therapeutic interventions. For instance, Enfuvirtide (T20), a peptide-based drug, functions as an HIV-1 cell fusion inhibitor by binding to the gp41 subunit and blocking the fusion process. Research continues into developing long-acting HIV-1 fusion inhibitory peptides, such as PEGylated C34, which have demonstrated efficacy in blocking viral entry. The comprehension of how VIRIP inhibits HIV-1 entry by specific binding to the gp41 fusion peptide also offers insights into the development of novel inhibitors.

The study of the HIV fusion peptide extends to its structural dynamics and interactions with membranes. For example, the HIV fusion peptide decreases bending energy and lowers the free energies of intermediates, thereby facilitating fusion. The conformation trajectory of the HIV-1 fusion peptide is an area of active research, aiming to fully elucidate its mechanism of action. Understanding the structure of HIV-1 gp41 with its membrane anchors and the role of the N-terminal ectodomain, which includes the fusion peptide, is vital for a comprehensive understanding of viral fusion.

The HIV-1 fusion peptide is also a focus in understanding the differences between naturally elicited and vaccine-elicited antibodies. Studies have compared the recognition of naturally elicited and vaccine-elicited antibodies targeting the fusion peptide (FP), which comprises the envelope (Env) glycoprotein. This research is essential for refining HIV vaccine strategies to induce more effective and broader immunity.

In summary, the HIV fusion peptide is a critical component for viral entry, acting as the initial mediator of HIV-1 envelope-mediated cell-cell fusion. Its conserved nature and vulnerability make it an attractive target for the development of both therapeutic agents and preventative HIV vaccines. Continued research into the HIV-1 fusion peptide immunogens, its interactions with cellular membranes, and the antibodies it elicits will be essential for cell entry and vaccine design and ultimately contribute to advancing research towards an effective AIDS/HIV vaccine. The insights gained from studying the HIV fusion peptide have helped to advance the field significantly.